AstraZeneca is a global biopharmaceutical company that focuses on the research, development, and manufacturing of a wide range of prescription medications. The company's primary areas of expertise include oncology, respiratory diseases, cardiovascular systems, and immunology, with a commitment to advancing innovative treatments that improve patient outcomes. AstraZeneca collaborates with healthcare professionals, researchers, and academic institutions to drive scientific advancements and ensure that their therapies reach those in need. Through its extensive portfolio, the company aims to address some of the world’s most pressing health challenges while maintaining a strong emphasis on sustainability and corporate responsibility.
Updated results from the OlympiA Phase III trial showed AstraZeneca and Merck & Co., Inc’s, known as MSD outside of the US and Canada, LYNPARZA® (olaparib) demonstrated sustained, clinically meaningful improvements in overall survival (OS), invasive disease-free survival (IDFS) and distant disease-free survival (DDFS) at six years for patients with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer.
Datopotamab deruxtecan (Dato-DXd) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) with disease progression on or after treatment with an EGFR-tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy.
Positive results from the AMPLIFY Phase III trial showed AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with venetoclax demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemoimmunotherapy in previously untreated adult patients with chronic lymphocytic leukemia (CLL).
AstraZeneca's Imfinzi gains FDA Priority Review for bladder cancer. Key trial data shows improved survival and progression outcomes in treated patients.
AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) has been accepted and granted Priority Review in the US for the treatment of patients with muscle-invasive bladder cancer (MIBC).
AstraZeneca's Imfinzi gains FDA approval for LS-SCLC after ADRIATIC trial shows survival benefits. Separate trials explore additional cancer therapies.
AstraZeneca’s IMFINZI® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
Law Offices of Howard G. Smith announces an investigation on behalf of AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) investors concerning the Company’s possible violations of federal securities laws.
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) investors concerning the Company’s possible violations of the federal securities laws.
The Law Offices of Frank R. Cruz announces an investigation of AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) on behalf of investors concerning the Company’s possible violations of federal securities laws.
Given the S&P's strong performance in the last year, momentum stock plays are those that have exceeded that high bar; here are three companies with potential.
Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca’s TRUQAP® (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) versus abiraterone and ADT with placebo in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC).
AstraZeneca today pledged $3.5 million to nonprofit organizations across the US as part of Accelerate Change Together (ACT) on Health Equity, an initiative to improve access, affordability and outcomes for patients in urban, suburban and rural communities. This brings the total contributions from the program to more than $15 million to date.
Thanks to the change in the Health and Human Services Department, 'big pharma' stocks are one of the very few sectors in equity-land that are seemingly unhappy about the forthcoming administration.
